Apimeds Pharmaceuticals US (APUS) Payables (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Payables for 4 consecutive years, with $8.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 7376.23% year-over-year to $8.9 million; the trailing twelve-month figure through Jun 2026 stood at $8.9 million (up 7376.23% YoY), and the FY2025 full-year result was $7.1 million, up 743.0% from the prior year.
• Payables climbed to $8.9 million in Q2 2026 per APUS's latest filing, from $7.1 million in the prior quarter.
• Across five years, Payables topped out at $8.9 million in Q2 2026 and bottomed at $119138.0 in Q2 2025.
• Historically, Payables has averaged $2.7 million across 4 years, with a median of $841191.0 in 2024.
• The sharpest annual moves came in 2024 and 2026: Payables jumped 161.78% in 2024, then jumped 7376.23% in 2026.
• Over 4 years, Payables stood at $321329.0 in 2023, then jumped by 161.78% to $841191.0 in 2024, then jumped by 743.0% to $7.1 million in 2025, then rose by 25.61% to $8.9 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $8.9 million, $7.1 million, and $567633.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.